Telomir-1 reactivates tumor suppressor genes in prostate cancer models

Telomir Pharmaceuticals has announced new preclinical data demonstrating that its investigational therapy, Telomir-1, reactivates two critical tumor suppressor genes—MASPIN and RASSF1A—in aggressive prostate cancer models. These genes are often silenced through DNA hypermethylation, a common mechani…